On Dec 19, 2025, the US Food and Drug Administration (FDA) announced a major milestone by qualifying total hip bone mineral density (BMD), assessed by dual-energy X-ray absorptiometry, as a surrogate ...
CVS Caremark will begin offering osteoporosis biosimilars Ospomyv and Stoboclo, as well as generic teriparatide, Bonsity and ...
CVS Health said on Thursday it would swap out Amgen and Eli Lilly's bone disease treatments for lower-cost alternatives in ...
CVS Health® (NYSE: CVS) today announced new steps to further help customers expand adoption of lower-cost biosimilar medications. Effective April 1, 2026, CVS Caremark will begin offering osteoporosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results